Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 16/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | LITAF | Q99732 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22988156 | 0.91 | ADORA2A (0.39) | ADORA2AADORA1ADORA2B | |
| SCHEMBL31149998 | 0.90 | PIM1 (0.35) | ADORA2AADORA1ADORA2B | |
| SCHEMBL22979137 | 0.90 | PIM1 (0.35) | ADORA2AADORA1ADORA2BHSP90AB1TNF | |
| SCHEMBL22978999 | 0.90 | PIM1 (0.35) | ADORA2AADORA1ADORA2B | |
| SCHEMBL22988433 | 0.90 | PIM1 (0.35) | ADORA2AADORA1ADORA2B | |
| SCHEMBL29645678 | 0.90 | PIM1 (0.35) | ADORA2AADORA1ADORA2BHSP90AB1TNF | |
| SCHEMBL29648877 | 0.90 | PIM1 (0.35) | ADORA2AADORA1ADORA2B | |
| SCHEMBL22980020 | 0.89 | ADORA2A (0.38) | ADORA2AADORA1KCNH2 | |
| SCHEMBL22979685 | 0.88 | PIM1 (0.34) | ADORA2AADORA1KCNH2ADORA2BTP53 | |
| SCHEMBL22988377 | 0.88 | ADORA2A (0.38) | ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114466850-B | [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine | 拜耳股份有限公司 | 2024-09-10 | — | — | CN | claimed |
| EP-4013508-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | Bayer Aktiengesellschaft (DE) | 2022-06-22 | — | — | EP | claimed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | claimed |
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-13 | — | — | US | disclosed |
| WO-2021028382-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230113037-A1 | [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES | AHR, HRH4, HRH1 | ADORA2A 103/4885ADORA1 21/4885KCNH2 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.